Information on this page is intended for Ireland healthcare professionals only and may contain promotional material
Global Presence
Tillotts has an increasing global presence with a network of affiliates in Europe and gastroenterology-focused partners throughout the world. Our products are currently present in about 65 countries in Europe, North and South America, Africa, Asia and Oceania.
Tillotts’ Vision is based on seven strategic pillars:
- Geographic Presence: Global product reach. Promotion predominantly via Group affiliates in strategic markets. In other markets through selected strategic partnerships.
- Portfolio: GI and other selected specialty therapeutics.
- Core Competencies: Promotion and medical management: strong network efficiently reaching stakeholders. R&D: identifying and meeting medical needs. Business Development and Licencing: trusted business partner in the global life science community. Management: entrepreneurial and focused, fast and efficient decision-making.
- R&D & Pipeline (Zeria Group Innvovation): Research builds the pipeline through internal development, as well as by in-licensing and selective acquisitions
- Collaboration: Close collaboration within the Zeria Group. Strategic collaborations with R&D partners: for sharing know-how, risk and cost. Within academia: for accessing innovation. With other pharma companies: for marketing and medical management outside the Group’s reach.
- Stakeholders: Close collaboration with healthcare professionals, patients, payers, shareholders & investors. Effective collaboration with authorities. Always following strict ethical guidelines.
- Technology: Innovative communication, production-supply-distribution, process management and R&D technologies.
Zeria Group
Zeria Pharmaceutical Co., Ltd. (Zeria) is Tillotts’ parent company. Zeria is dedicated to research & development, manufacturing and sales of ethical pharmaceuticals, as well as consumer healthcare products.
It was founded in 1955 in Tokyo and employs more than 1,800 people. Zeria is on the JP stock market (4559:JP) and operates internationally through a large network of subsidiaries. Zeria holds a leading position within the gastroenterology field in Japan.
Mission
We support and collaborate with healthcare professionals around the world to continuously evolve understanding in the field of gastroenterology and other specialist therapeutic areas.
We deliver high quality medicines and educational support that improve patient lives.
We take pride in our unique culture, that is based on our corporate values, guiding us in our every day business and allowing our diverse workforce to develop and deliver their full potential. We treat our employees as well as our business partners with fairness and respect. In striving towards our Vision 2030, we always demonstrate passion, rewarding entrepreneurial spirit and outstanding performance. We encourage our employees to see the bigger picture, challenge the status quo and embrace change.
As an attractive employer, we invest in our people by offering a state-of-the-art work environment, and providing room for our employees to create a modern and flexible work-life-balance.
To our shareholders we provide both value and attractive, sustainable returns.
NP-TP-IE-00011 | October 2025
The information on the following pages is only intended for patients within Ireland who have been prescribed Asacolon, Dificlir or Entocort CR 3 mg Capsules
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie/report-an-issue/medicines-for-human-use/side-effects.
Adverse events should also be reported to Tillotts Pharma UK and Ireland on +353 1 2942015 or pvireland@tillotts.com
You are about to leave tillotts.ie for an external website. Tillotts is not responsible for the content of other websites.